Page 67 - 2017 V1 InsideOut

NewIndications FDA approved
Imbruvica®
Imbruvica (ibrutinib), manufactured by Pharmacyclics, Inc., is now ap- proved by the FDA for treatment of marginal zone lymphoma (MZL) in pa- tients who require systemic therapy and have received at least one prior anti-CD20 based therapy. Imbruvica is the first and only FDA-approved treatment specifically indicated for MZL. MZL is a rare, slow-growing cancer, accounting for approximately 8 percent of all non-Hodgkin lymphomas. Until now, MZL patients were without an FDA-approved treatment option specifically indicated for this disease. This milestone marks the seventh FDA approval for Imbruvica, and the fifth unique blood cancer indication.
For specific product ordering information, please see page 75 in our Product Catalog.
Keytruda®
Keytruda (pembrolizumab), manufactured by Merck, is now approved for the treatment of classical Hodgkin lymphoma (cHL) for both pediatric and adult patients whose treatment was not successful or have relapsed after three or more prior lines of therapy.
For specific product ordering information, please see page 75 in our Product Catalog.
Opdivo®
Opdivo (nivolumab), manufactured by Bristol-Myers Squibb, is now approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer, who have disease progression during or following platinum-containing chemo- therapy, or who have disease progression within 12 months of neoadju- vant or adjuvant treatment with platinum-containing chemotherapy.
For specific product ordering information, please see page 76 in our Product Catalog.
Ne
Find product ordering information on all ASD Healthcare products in our Product Catalog on page 65.
Get recent updates to new products and new indications at asdhealthcare.com/ products/new-products.
ASD Healthcare | 63